ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 985

Inverse Relation Between the tumor Necrosis Factor Promoter Methylation and Trascript Leveles in Leukocytes From Patients with Rheumatoid Arthritis

James R. Maxwell1, Lyndsey H. Taylor2, Richardo A. Pachecho2, Neil Lawrence2, Gordon W. Duff3, M. Dawn. Teare2 and Anthony G. Wilson4, 1University of Sheffield, Sheffield, United Kingdom, 2University of Sheffield, United Kingdom, 3Royal Hallamshire Hospital, Sheffield, United Kingdom, 4Infection and Immunity, University of Sheffield, Sheffield, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Epigenetics, methylation and tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Genetics and Genomics of Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The importance of the epigenetic signature in RA is unclear but levels of methylation of CpG motifs in the TNF promoter are known to be important determinants of transcriptional activity.  In view of the central importance of this cytokine in RA we hypothesised that methylation of the TNF gene in peripheral blood cells might differ between RA patients and controls.  The primary objectives were to determine if CpG motifs in the TNF gene promoter were differentially methylated in RA compared with controls and if TNF mRNA levels correlated with DNA methylation.  We also determined whether methotrexate was associated with alterations in genomic or TNF promoter DNA methylation levels. 

Methods:

A cross-sectional RA population (n=218) and healthy controls (n=312) was used to investigate the primary objective.  A second population of RA patients starting MTX were recruited (n=33) and DNA and DAS28 scores were obtained prior to treatment and at 3 months.  Methylation of seven TNF 5′ CpG motifs (-349 to -78) and LINE-1, an assay of genomic mehtylation, in peripheral blood leucocytes were assessed by pyrosequencing and levels of TNF mRNA were measured using quantitative PCR.

Results:

Levels of methylation of 4 TNF CpGs (-170, -239, -245, -304) were higher in RA compared with controls (p=7.1×10-5 to 1.3×10-10) and TNF mRNA was 58% lower in RA cases (p=1.5 x10-10).  In both RA and controls negative correlations of TNF-245 methylation with TNF mRNA levels were detected (p=0.02 and 0.04 respectively).   There was no difference in LINE-1 or TNF methylation in MTX treated patients and no correlation between change in methylation with DAS28 response after 3 months.

Conclusion: Higher levels of methylation of the TNF promoter are present in RA leukocytes compared with controls, and levels of TNF mRNA were lower in the patients.  Methylation levels of TNF-245 were inversely correlated with TNF mRNA levels in both groups.  Treatment with MTX was not associated with changes in genomic or TNF methylation levels.  These results suggest that methylation of the TNF promoter is higher in RA compared with controls and that methylation of TNF-245 is an important regulatory mark for TNF expression.


Disclosure:

J. R. Maxwell,
None;

L. H. Taylor,
None;

R. A. Pachecho,
None;

N. Lawrence,
None;

G. W. Duff,
None;

M. D. Teare,
None;

A. G. Wilson,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inverse-relation-between-the-tumor-necrosis-factor-promoter-methylation-and-trascript-leveles-in-leukocytes-from-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology